Table XII.
Changes in observed CVD parameters.
| Parameter | Group | N decreased (%) | N unaltered (%) | N increased (%) | P-value |
|---|---|---|---|---|---|
| SBP | Verum | 21 (80.8) | 0 (0.0) | 5 (19.2) | <0.001 |
| Placebo | 18 (62.1) | 0 (0.0) | 11 (37.0) | 0.091 | |
| DBP | Verum | 22 (84.6) | 0 (0.0) | 4 (15.4) | <0.001 |
| Placebo | 17 (58.6) | 2 (6.9) | 10 (34.5) | 0.051 | |
| TG | Verum | 20 (76.9) | 0 (0.0) | 6 (23.1) | 0.022 |
| Placebo | 12 (41.4) | 0 (0.0) | 17 (58.6) | 0.408 | |
| SCORE | Verum | 8 (30,8) | 17 (65.4) | 1 (3.8) | 0.039 |
| Placebo | 4 (13.8) | 23 (79.3) | 2 (6.9) | 0.688 |
CVD, cardiovascular disease; N, number of participants; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides.